| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Dec 7, 2025 | Dec 9, 2025 | OmniAb, Inc. | CFO | Sell | 46.3 | -23,922 | -8.65% | ✗ | $46.9K |
| Jun 12, 2025 | Jun 16, 2025 | Xencor Inc | Director | Sell | 91.3 | +10,693 | 112.68% | ✓ | $27.6K |
| Apr 7, 2025 | Apr 7, 2025 | OmniAb, Inc. | CFO | Sell | 46.3 | -7,206 | -3.12% | ✗ | $14.4K |
| Apr 1, 2025 | Apr 1, 2025 | OmniAb, Inc. | CFO | Sell | 46.3 | -11,963 | -5.21% | ✗ | $28.4K |
| Feb 16, 2025 | Feb 19, 2025 | OmniAb, Inc. | CFO | Sell | 46.3 | -7,255 | -3.40% | ✗ | $26.6K |
| Jan 17, 2025 | Jan 22, 2025 | OmniAb, Inc. | CFO | Sell | 90.0 | +12,059 | 6.01% | ✗ | $50.3K |
| Dec 7, 2024 | Dec 10, 2024 | OmniAb, Inc. | CFO | Sell | 42.5 | -23,871 | -10.63% | ✗ | $98.6K |
| Sep 27, 2024 | Oct 1, 2024 | Xencor Inc | Director | Sell | 15.0 | -2,503 | -20.87% | ✓ | $51.8K |
| Apr 7, 2024 | Apr 9, 2024 | OmniAb, Inc. | CFO | Sell | 46.3 | -6,954 | -3.79% | ✗ | $36.6K |
| Apr 1, 2024 | Apr 2, 2024 | OmniAb, Inc. | CFO | Sell | 42.5 | -11,849 | -6.51% | ✗ | $64.7K |
| Mar 6, 2024 | Mar 7, 2024 | Xencor Inc | Director | Sell | 20.0 | -14,000 | -69.98% | ✗ | $324.5K |
| Dec 7, 2023 | Dec 11, 2023 | OmniAb, Inc. | CFO | Sell | 42.5 | -16,081 | -9.20% | ✗ | $78K |
| Apr 1, 2023 | Apr 4, 2023 | OmniAb, Inc. | CFO | Sell | 46.3 | -8,042 | -2.66% | ✗ | $29.6K |
| Dec 1, 2022 | Dec 5, 2022 | OmniAb, Inc. | CFO | Sell | 26.3 | -6,733 | -3.96% | ✗ | $22.6K |
| Nov 28, 2022 | Nov 29, 2022 | OmniAb, Inc. | CFO | Buy | 86.3 | +10,000 | 6.25% | ✗ | $28.1K |
| Aug 9, 2011 | Aug 10, 2011 | HALOZYME THERAPEUTICS, INC. | CFO | Buy | 91.3 | +8,000 | 100.00% | ✗ | $47K |